Deferred Tax Assets, Valuation Allowance of Krystal Biotech, Inc. from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Krystal Biotech, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • Krystal Biotech, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $14,214,000, a 79% decline year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Krystal Biotech, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $14,214,000 -$53,880,000 -79% 31 Dec 2025 10-K 17 Feb 2026 2025 FY
Q4 2024 $68,094,000 -$8,901,000 -12% 31 Dec 2024 10-K 17 Feb 2026 2025 FY
Q4 2023 $76,995,000 -$5,518,000 -6.7% 31 Dec 2023 10-K 19 Feb 2025 2024 FY
Q4 2022 $82,513,000 +$39,781,000 +93% 31 Dec 2022 10-K 26 Feb 2024 2023 FY
Q4 2021 $42,732,000 +$20,689,000 +94% 31 Dec 2021 10-K 27 Feb 2023 2021 FY
Q4 2020 $22,043,000 +$11,112,000 +102% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q4 2019 $10,931,000 +$6,471,000 +145% 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q4 2018 $4,460,000 +$2,296,000 +106% 31 Dec 2018 10-K 10 Mar 2020 2019 FY
Q4 2017 $2,164,000 31 Dec 2017 10-K 12 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.